Patents by Inventor Lucy Boulter

Lucy Boulter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • High affinity NY-ESO T cell receptors
    Patent number: 8367804
    Abstract: The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC-HLA-A*0201, the SLLMWITQC SEQ ID NO:126 peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumour cells. The TCRs have a KD for the said peptide-HLA complex of less than or equal to 1 ?M and/or have an off-rate (koff) of 1×10?3 S?1 or slower.
    Type: Grant
    Filed: July 5, 2011
    Date of Patent: February 5, 2013
    Assignee: Immunocore Limited
    Inventors: Bent Karsten Jakobsen, Yi Li, Peter Eamon Molloy, Steven Mark Dunn, Lucy Boulter
  • High affinity NY-ESO T cell receptor
    Patent number: 8143376
    Abstract: The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC-HLA-A*0201, the SLLMWITQC (SEQ ID NO:126) peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumour cells. The TCRs have a KD for the said peptide-HLA complex of less than or equal to 1 ?M and/or have an off-rate (koff) of 1×10?3 S?1 or slower.
    Type: Grant
    Filed: May 18, 2005
    Date of Patent: March 27, 2012
    Assignee: Immunocore Limited
    Inventors: Jonathan Michael Boulter, Lucy Boulter, legal representative, Bent Karsten Jakobsen, Yi Li, Peter Eamon Molloy, Steven Mark Dunn
  • HIGH AFFINITY NY-ESO T CELL RECEPTORS
    Publication number: 20110262414
    Abstract: The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC-HLA-A*0201, the SLLMWITQC peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumour cells. The TCRs have a KD for the said that peptide-HLA complex of less than or equal to 1 ?M and/or have an off-rate (koff) of 1×10?3 S?1 or slower.
    Type: Application
    Filed: July 5, 2011
    Publication date: October 27, 2011
    Applicant: IMMUNOCORE LIMITED
    Inventors: Jonathan Michael Boulter, Bent Karsten Jakobsen, Yi Li, Peter Eamon Molloy, Steven Mark Dunn, Lucy Boulter
  • High affinity NY-ESO T cell receptors
    Patent number: 8008438
    Abstract: The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC (SEQ ID NO:126)-HLA-A*0201, the SLLMWITQC (SEQ ID NO:126) peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumor cells. The TCRs have a KD for the said that peptide-HLA complex of less than or equal to 1 ?M and/or have an off-rate (koff) of 1×10?3 S?1 or slower.
    Type: Grant
    Filed: August 11, 2010
    Date of Patent: August 30, 2011
    Assignee: Immunocore Limited
    Inventors: Jonathan Michael Boulter, Lucy Boulter, legal representative, Bent Karsten Jakobsen, Yi Li, Peter Eamon Molloy, Steven Mark Dunn
  • HIGH AFFINITY NY-ESO T CELL RECEPTORS
    Publication number: 20110014169
    Abstract: The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC-HLA-A*0201, the SLLMWITQC peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumour cells. The TCRs have a KD for the said that peptide-HLA complex of less than or equal to 1 ?M and/or have an off-rate (koff) of 1×10?3 S?1 or slower.
    Type: Application
    Filed: August 11, 2010
    Publication date: January 20, 2011
    Applicant: IMMUNOCORE LIMITED
    Inventors: Jonathan Michael Boulter, Bent Karsten Jakobsen, Yi Li, Peter Eamon Molloy, Steven Mark Dunn, Lucy Boulter
  • Method of improving T cell receptors
    Patent number: 7608410
    Abstract: A method of increasing the affinity and/or decreasing the off-rate of a given TCR specific for a given target pMHC, comprising creating a plurality of TCRs having an ? chain CDR2 sequence and/or a ? chain CDR2 sequence different from the corresponding CDR2 sequence(s) of the given TCR but having the same ? and ? CDR1 and CDR3 sequences as the given TCR, determining the affinity and/or off-rate of members of said plurality of TCRs for the target pMHC, and selecting one or more members having at least a 10-fold greater affinity for the target pMHC than the given TCR and/or a 10-fold slower off-rate for the target pMHC than the given TCR.
    Type: Grant
    Filed: October 7, 2008
    Date of Patent: October 27, 2009
    Assignee: Immunocore Limited
    Inventors: Steven Mark Dunn, Yi Li, Jonathan Michael Boulter, Lucy Boulter, legal representative